Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | TP53 | P04637 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31653785 | 0.82 | MAPT (0.45) | MAPTTP53GAARXFP1KDM4E | |
| SCHEMBL31653952 | 0.80 | KDM4E (0.44) | MAPTTP53GAAKDM4ELMNA | |
| SCHEMBL31653997 | 0.80 | MAPT (0.41) | MAPTTP53GAARXFP1KDM4E | |
| SCHEMBL31653721 | 0.76 | RORC (0.42) | MAPTTP53GAARXFP1KDM4E | |
| SCHEMBL31653799 | 0.73 | ALDH1A1 (0.45) | MAPTTP53GAARXFP1KDM4E | |
| SCHEMBL31653843 | 0.71 | TP53 (0.41) | MAPTTP53GAARXFP1KDM4E | |
| SCHEMBL31653720 | 0.69 | ALDH1A1 (0.42) | MAPTTP53GAARXFP1KDM4E | |
| SCHEMBL2056170 | 0.68 | EPHX2 (0.63) | MAPTGAALMNASMN1; SMN2 | |
| SCHEMBL31664544 | 0.66 | KDM4E (0.43) | MAPTTP53RXFP1KDM4ELMNA | |
| SCHEMBL10175640 | 0.65 | KDM4E (0.58) | MAPTTP53KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215006-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF WRN | INCYTE CORPORATION (US) | 2025-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215006-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF WRN | WRN, BLM, RECQL | MAPT 4466/4885TP53 11/4885GAA 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.